Home/Filings/4/0000950170-24-017405
4//SEC Filing

MCDADE MARK 4

Accession 0000950170-24-017405

CIK 0001786255other

Filed

Feb 19, 7:00 PM ET

Accepted

Feb 20, 7:38 PM ET

Size

11.6 KB

Accession

0000950170-24-017405

Insider Transaction Report

Form 4
Period: 2024-02-19
MCDADE MARK
10% Owner
Transactions
  • Disposition from Tender

    Common Stock

    2024-02-1955,7860 total
  • Disposition from Tender

    Common Stock

    2024-02-193,510,2280 total(indirect: By Qiming U.S. Healthcare Fund II, L.P.)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-02-1922,2780 total
    Exercise: $6.25Common Stock (22,278 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2024-02-1917,0000 total
    Exercise: $9.89Common Stock (17,000 underlying)
Footnotes (2)
  • [F1]In connection with the terms of an Agreement and Plan of Merger, dated as of December 11, 2023 (the "Merger Agreement"), by and among the Issuer, AstraZeneca Finance and Holdings Inc. ("Parent"), and Isochrone Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock at a purchase price per share of (i) $15.00 plus (ii) one non-tradable contingent value right ("CVR") per share representing the right to receive a contingent payment of up to $5.00 in cash upon achievement of specified milestones (collectively, the "Offer Price"). After completion of the tender offer, Purchaser merged with and into the Issuer (the "Merger"), effective as of February 19, 2024 (the "Effective Time"), with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent.
  • [F2]Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, this stock option was cancelled and converted into the right to receive, subject to the terms of the Merger Agreement, (a) an amount in cash equal to the product obtained by multiplying (1) the aggregate number of shares underlying such option immediately prior to the Effective Time by (2) an amount equal to (A) $15.00 less (B) the exercise price of such option, plus (b) one CVR for each share underlying such option immediately prior to the Effective Time.

Documents

1 file

Issuer

Icosavax, Inc.

CIK 0001786255

Entity typeother

Related Parties

1
  • filerCIK 0001242126

Filing Metadata

Form type
4
Filed
Feb 19, 7:00 PM ET
Accepted
Feb 20, 7:38 PM ET
Size
11.6 KB